Headache and Migraine

The PACAP pathway has shown promise as a potential novel therapeutic target in the treatment of migraine.

Neurology News Network for the week ending February 20, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 19, 2021.

The director of the Montefiore Headache Center discussed the impact of halving headache days for patients with migraine.

ElectroCore announced that the expanded indication, noting that gammaCore is now the only acute and preventive option approved for both adult and adolescent migraine.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 12, 2021.

The director of the Montefiore Headache Center discussed how rimegepant was observed to produce clinically meaningful improvements in migraine prevention.

Here's what is coming soon to NeurologyLive.

Study results suggest that fewer than 10% of the more than 2000 migraine episodes analyzed were associated with increased levels of perceived stress.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 5, 2021.

Observation of pain freedom at 30 minutes was more accurate than the observation of relief at 30 minutes in predicting pain freedom at 2 hours.

Barbara Karp, MD, and Sharon Meropol, MD, discuss the recently launched NeuroCOVID databank from the NIH, which will track neurologic symptoms associated with COVID-19.

After Theranica’s remote electrical neuromodulation was approved for those aged 12 years and older with migraine, study investigator Jennifer McVige, MD, MA, shared her insight.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.

After winning FDA approval in October 2020, the new expanded indication includes adolescents aged 12 and older with episodic or chronic migraine.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 22, 2021.

If approved, INP104 would be the first and only delivery system to explore the vascular-rich upper nasal space as a therapeutically viable treatment pathway.

The director of the Montefiore Headache Center discussed how his team’s findings can change the way physicians think about treating migraine.